New research reveals tau seed propagation patterns in Alzheimer's

Researchers at the University of Alabama at Birmingham, working with collaborators at Rush University Medical Center in Chicago and SUNY Upstate Medical University in Syracuse, report that tau seeds drive neurofibrillary tangle formation across cortical regions through pathways shaped by each individual's brain connectivity, according to a study published April 8, 2026 in Neuron.

The findings position individual-specific functional connectivity — not just the pathological agent itself — as a determinant of where and how tau pathology spread occurs in Alzheimer's disease.

The postmortem study drew on 128 participants from the ROSMAP cohort, with a mean age at death of 91 years. Researchers isolated synaptosome fractions from two brain regions — the inferior temporal gyrus (ITG) and superior frontal gyrus (SFG) — and quantified tau seed bioactivity using a Tau RD P301S-FRET biosensor cell assay. A subset of 102 participants had antemortem fMRI data available, allowing the team to link premortem brain connectivity patterns to postmortem tau seeding measures. Causal inference was established through Mendelian randomization using genotype data from 119 participants.

ITG showed significantly higher tau seed bioactivity than SFG, consistent with the earlier involvement of temporal regions in Braak staging. Tau seed bioactivity in both regions correlated with phospho-tau epitopes at T181, S199, T231, and S396, with correlations stronger in ITG than SFG. Both ITG and SFG tau seed bioactivity associated with worse antemortem cognitive performance, with associations persisting after controlling for amyloid burden.

Mendelian randomization provided causal support for directional trans-synaptic tau propagation from temporal to frontal cortex. ITG tau seed bioactivity causally predicted SFG tau seed bioactivity, with the two-stage least squares estimate reaching statistical significance. The effect persisted after controlling for confounders, supporting a model in which misfolded tau species travel from earlier-affected temporal regions to distal frontal areas via synaptic pathways.

The study's structural equation modeling added a further layer: ITG-SFG functional connectivity, measured by fMRI, moderated the relationship between ITG and SFG tau seed bioactivity. Higher connectivity between the two regions was associated with stronger coupling of tau seeding across them. A moderated mediation model confirmed that ITG-SFG connectivity moderated the effect of ITG tau seeds on SFG neurofibrillary tangles, mediated through SFG tau seeds, with the interaction term reaching significance at p = 0.036. The authors describe this as the largest investigation of tau seed bioactivity in human brains to date paired with fMRI data.

Why it matters

The work addresses a recognized gap in Alzheimer's disease neuropathology research. Population-level staging systems such as Braak describe average patterns of tau accumulation but do not account for the heterogeneity in disease trajectory observed across patients. By linking individual fMRI connectivity data to postmortem tau seeding measures, the UAB-Rush-SUNY team provides a framework in which a patient's own brain wiring contributes to the route and pace of tau seed propagation — a finding with potential implications for patient stratification in anti-tau clinical programs.

The anti-tau therapeutic landscape is active but has not yet produced an approved agent. Bristol Myers Squibb's BMS-986446, an anti-MTBR tau monoclonal antibody targeting the domain most implicated in seeding, is in Phase II testing in early Alzheimer's disease (NCT06268886, active, not recruiting). A multi-arm Alzheimer's Tau Platform Master Protocol (NCT06957418) is evaluating tau-directed agents alone and in combination with donanemab, Eli Lilly's approved amyloid-clearing antibody. Prior tau-directed programs including Roche/Genentech's semorinemab, which completed and was terminated across two Phase II studies, have not demonstrated clinical benefit, underscoring the need for better mechanistic understanding of how tau spreads in individual patients.

The current study is a preclinical mechanistic investigation. The translational relevance lies in the framework it establishes: if individual connectome architecture shapes tau propagation routes, then connectivity data could inform which patients are at risk for rapid inter-regional spread and which therapeutic windows might be most relevant for intervention. The authors note that the findings reinforce the rationale for targeting extracellular tau seeds to slow disease progression.

Remaining challenges include the observational and postmortem nature of the data, the predominantly older and female cohort, and the use of functional rather than structural connectivity as the moderating variable. Whether individualized connectivity-based models can be prospectively validated using in vivo tau PET imaging — currently being studied with tracers including 18F-RO948 (NCT06731842) — remains an open question. The study provides a mechanistic rationale for that line of investigation but does not itself resolve it.

Meta description: UAB and Rush researchers report individual brain connectivity moderates tau seed propagation to drive neurofibrillary tangle spread in Alzheimer's disease.

---

Spot something wrong? Report an issue with this article